Seeking Alpha

GSK (GSK) begins Phase III trials of its mepolizumab antibody treatment for severe refractory...

GSK (GSK) begins Phase III trials of its mepolizumab antibody treatment for severe refractory asthma after an earlier study showed that it almost halved the number of attacks in patients. Around 4% of asthma sufferers experience the severe form of the disease.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs